SpectronRx has signed a commercial supply agreement with Cellectar Biosciences, Inc. to manufacture iopofosine I 131, a promising first-in-class cancer therapy. This agreement marks a significant step in the development and global distribution of the drug, which has shown efficacy
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on central nervous system (CNS) cancers, has entered a Manufacturing Services Agreement (MSA) with SpectronRx, a radiopharmaceutical contract development and manufacturing organisation (CDMO). The partnership will enable the production of
SpectronRx, based in Indianapolis, is expanding its operations by establishing a new radiolabeling facility in Belgium. The company announced a binding agreement to build the plant at the Belgian Nuclear Research Center (SCK CEN) in Mol. The construction is expected
